Trends in viral load and CD4 cell count monitoring among adults with HIV in the Asia-Pacific region: A multicentre observational cohort study of the TREAT Asia HIV Observational Database, 2003–2018

Introduction Viral load (VL) testing is recommended for monitoring antiretroviral therapy (ART), whereas CD4 testing is increasingly targeted. Changes in these practices across Asia-Pacific remain unclear. We examined trends in VL and CD4 testing rates and their associations with AIDS diagnosis and mortality. Methods We analysed multicentre cohort data from adults receiving ART during 2003–2018 using Poisson and Fine-Gray competing-risk regression. Results Among 8,446 patients, VL testing rates remained steady at one test per person-year during 2003−2018. Increased VL testing was associated with more frequent CD4 testing (>2 tests in the previous year; incidence rate ratio (IRR)=1.57, 95%CI 1.53–1.60), later follow-up years (2008−2012: IRR = 1.15, 95%CI 1.12–1.18; 2013−2015: IRR = 1.07, 95%CI 1.04–1.10), older age (31−40years: IRR = 1.06, 95%CI 1.03–1.08; 41−50years: IRR = 1.08, 95%CI 1.05–1.11; > 50years: IRR = 1.07, 95%CI 1.03–1.11), higher current VL (401−1000 copies/mL: IRR = 1.16, 95%CI 1.09–1.24; > 1000 copies/mL: IRR = 1.07, 95%CI 1.04–1.11), initial ART regimen (nucleoside/nucleotide reverse transcriptase inhibitor plus protease inhibitor (NRTI+PI): IRR = 1.07, 95%CI 1.04–1.10; other combinations: IRR = 1.11, 95%CI 1.05–1.17), and higher country income levels (upper-middle: IRR = 2.17, 95%CI 2.11–2.23; high: IRR = 3.14, 95%CI 3.03–3.26). CD4 testing rates decreased from 2.04 to 1.06 tests per person-year over the same period. Lower CD4 testing rate was associated with HIV exposure mode (men who have sex with men (MSM): IRR = 0.94, 95%CI 0.92–0.96; injecting drug use (IDU): IRR = 0.93, 95%CI 0.90–0.97; other/unknown: IRR = 0.90, 95%CI 0.87–0.93), higher current CD4 (201−350 cells/µL: IRR = 0.95, 95%CI 0.93–0.97; 351−500 cells/µL: IRR = 0.89, 95%CI 0.87–0.91; > 500 cells/µL: IRR = 0.85, 95%CI 0.83–0.87) and receiving an NRTI+PI first-line combination (IRR = 0.96, 95% CI 0.94–0.98). VL and CD4 testing rates were not significantly associated with AIDS diagnosis. However, having >2 CD4 tests in the previous year was associated with higher mortality risk. Conclusion VL testing was broadly consistent with annual monitoring, although individual gaps may remain. Differentiated strategies should maintain annual VL testing and targeted CD4 testing for advanced HIV disease.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-19
DOI
https://doi.org/10.1371/journal.pone.0346353
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trends in viral load and CD4 cell count monitoring among adults with HIV in the Asia-Pacific region: A multicentre observational cohort study of the TREAT Asia HIV Observational Database, 2003–2018

Thach Ngoc Pham, Romanee Chaiwarith, Mark KU Pasayan, Junko Tanuma et al.
1 links
PLoS ONE
HIV/AIDS Research and Interventions
article

Trends in viral load and CD4 cell count monitoring among adults with HIV in the Asia-Pacific region: A multicentre observational cohort study of the TREAT Asia HIV Observational Database, 2003–2018

Thach Ngoc Pham, Romanee Chaiwarith, Mark KU Pasayan, Junko Tanuma, Cuong Duy, Rossana A. Ditangco, Anchalee Avihingsanon, Sanjay N. Pujari, Evy Yunihastuti, Oon Tek Ng, Fujie Zhang, Awachana Jiamsakul, Jeremy L. Ross, Y J Chan, on behalf of IeDEA Asia-Pacific, Suwimon Khusuwan, Sasisopin Kiertiburanakul, I Ketut Agus Somia, Nagalingeswaran Kumarasamy, Yasmin Mohamed Gani, Iskandar Azwa, Rohidas T. Borse, Man Po Lee, Vohith Khol, Jun Yong Choi
article en

Abstract

Introduction Viral load (VL) testing is recommended for monitoring antiretroviral therapy (ART), whereas CD4 testing is increasingly targeted. Changes in these practices across Asia-Pacific remain unclear. We examined trends in VL and CD4 testing rates and their associations with AIDS diagnosis and mortality. Methods We analysed multicentre cohort data from adults receiving ART during 2003–2018 using Poisson and Fine-Gray competing-risk regression. Results Among 8,446 patients, VL testing rates remained steady at one test per person-year during 2003−2018. Increased VL testing was associated with more frequent CD4 testing (>2 tests in the previous year; incidence rate ratio (IRR)=1.57, 95%CI 1.53–1.60), later follow-up years (2008−2012: IRR = 1.15, 95%CI 1.12–1.18; 2013−2015: IRR = 1.07, 95%CI 1.04–1.10), older age (31−40years: IRR = 1.06, 95%CI 1.03–1.08; 41−50years: IRR = 1.08, 95%CI 1.05–1.11; > 50years: IRR = 1.07, 95%CI 1.03–1.11), higher current VL (401−1000 copies/mL: IRR = 1.16, 95%CI 1.09–1.24; > 1000 copies/mL: IRR = 1.07, 95%CI 1.04–1.11), initial ART regimen (nucleoside/nucleotide reverse transcriptase inhibitor plus protease inhibitor (NRTI+PI): IRR = 1.07, 95%CI 1.04–1.10; other combinations: IRR = 1.11, 95%CI 1.05–1.17), and higher country income levels (upper-middle: IRR = 2.17, 95%CI 2.11–2.23; high: IRR = 3.14, 95%CI 3.03–3.26). CD4 testing rates decreased from 2.04 to 1.06 tests per person-year over the same period. Lower CD4 testing rate was associated with HIV exposure mode (men who have sex with men (MSM): IRR = 0.94, 95%CI 0.92–0.96; injecting drug use (IDU): IRR = 0.93, 95%CI 0.90–0.97; other/unknown: IRR = 0.90, 95%CI 0.87–0.93), higher current CD4 (201−350 cells/µL: IRR = 0.95, 95%CI 0.93–0.97; 351−500 cells/µL: IRR = 0.89, 95%CI 0.87–0.91; > 500 cells/µL: IRR = 0.85, 95%CI 0.83–0.87) and receiving an NRTI+PI first-line combination (IRR = 0.96, 95% CI 0.94–0.98). VL and CD4 testing rates were not significantly associated with AIDS diagnosis. However, having >2 CD4 tests in the previous year was associated with higher mortality risk. Conclusion VL testing was broadly consistent with annual monitoring, although individual gaps may remain. Differentiated strategies should maintain annual VL testing and targeted CD4 testing for advanced HIV disease.

PLoS ONEVol. 21(11)
Udayana University (ID), Thai Red Cross Society (TH), Capital Medical University (CN), Yonsei University (KR), B. J. Medical College & Sassoon Hospital (IN), Mahidol University (TH), Research Institute for Tropical Medicine (PH), Voluntary Health Services Hospital (IN), Tan Tock Seng Hospital (SG), American Foundation for AIDS Research (US), Taipei Veterans General Hospital (TW), University of Indonesia (ID), UNSW Sydney (AU), University of Malaya (MY), National Center for Global Health and Medicine (JP), National Center for HIV/AIDS, Dermatology and STD (KH), ChiangRai Prachanukroh Hospital (TH), HIV Netherlands Australia Thailand Research Collaboration (TH), Hospital Sungai Buloh (MY), Beijing Ditan Hospital (CN), National Centre for Infectious Diseases (SG), Bạch Mai Hospital (VN), Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (ID), Hospital for Tropical Diseases (VN), Queen Elizabeth Hospital (CN), Kirby Institute (AU), Chiang Mai University (TH)
amfAR, The Foundation for AIDS Research, Australian Government, University of New South Wales, National Institutes of Health, National Institute of Allergy and Infectious Diseases
Good health and well-being
HIV/AIDS Research and Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon